Therapeutics Pipeline

Explore our innovative development pipeline for gastrointestinal cancers.

TriAx/Bispecific Antibody Platform
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB202
Learn more
CDH17 / CD3 TCE
Basket GI cancers
Undisclosed
Learn more
Trispecific TCE
Advanced GI cancers
Antibody Drug Conjugate (ADC)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB1035
Biparatopic ADC
CDH17-positive tumors
ARB1002
FDA-approved drug
CDH17-positive tumors
Undisclosed
Photocaged drug
CDH17-positive tumors
Advanced Cell Therapy (CAR)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB001
CAR-T
mCRC
ARB011
CAR-NK/T
Advanced GI cancers

Diagnostics Pipeline

Explore our innovative development pipeline for gastrointestinal cancers.

Platform
Intended Use
Prototyping / Optimization
Manufacturing
Clinical Studies
Launch
CDH17 - IHC Test
GI cancer diagnostics
CDH17 - Blood Test
CRC screening / surveillance
CDH17 - POCT
Point-of-Care Test

Join our research

Explore our pipeline

Discover our groundbreaking immunotherapy platforms for gastrointestinal cancers.

Contact Us